[Publication]: Sterile Inflammation Induces Vasculopathy and Chronic Lung Injury in Murine Sickle Cell Disease October 2024
Dr. Pritchard and colleagues at MCW along with collaborators at rngen demonstrated that KYC may be effective in treating vasculopathy and lung damage found in animal models of sickle cell disease.
[View publication: https://www.sciencedirect.com/science/article/abs/pii/S0891584924000601?via%3Dihub]
[Publication]: Role of Myeloperoxidase, Oxidative Stress, and Inflammation in Bronchopulmonary Dysplasia July 23, 2024
Bronchopulmonary dysplasia is a complex lung disorder caused by multiple etiologies. In this review article, rngen and the Medical College of Wisconsin researchers compiled ample evidence to demonstrate an intricate interaction between myeloperoxidase, oxidative stress, and inflammation to form a self-perpetuating destructive cycle. As a systems pharmacology agent, KYC mitigates all three pillars to attenuate bronchopulmonary dysplasia.
[View publication: https://pmc.ncbi.nlm.nih.gov/articles/PMC11351552/]
[Publication]: Endoplasmic Reticulum Stress in Bronchopulmonary Dysplasia: Contributor or Consequence? June 2024
In a recent publication in Cells Dr. Teng and his collaborators at rngen discussed the role of ER Stress in bronchopulmonary dysplasia BPD, and what that means for developing effective therapies against BPD.
[View publication: https://www.mdpi.com/2073-4409/13/21/1774]
[Publication]: Temporal Dynamics of Inflammation and Oxidative Stress in Bronchopulmonary Dysplasia May 2024
In a recent Int. J. Mol. Sci. paper rngen scientists demonstrated that KYC can mitigate both inflammation and oxidative stress in a rat pup animal model of bronchopulmonary dysplasia.
[View publication: https://www.mdpi.com/1422-0067/25/18/10145]
[Publication]: Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia February 2024
In this authoritative lung journal, rngen and the Medical College of Wisconsin researchers demonstrated that cellular senescence contributes to the progression of bronchopulmonary dysplasia. Daily KYC treatment reduced cellular senescence and successfully ameliorated.
[View publication: https://doi.org/10.1165/rcmb.2023-0038OC]
[Grant]: NIH R44 Phase II Awarded for BPD Program March 2023
rngen was awarded $2.8M in non-dilutive NIH funding from NHLBI to advance KYC for bronchopulmonary dysplasia. This milestone builds on our successful Phase I data and expands our vPharma Network’s focus on neonatal diseases.
[Read More: https://reporter.nih.gov/search/jd51Y6huXkK31EUN3kgGqQ/project-details/10691950]
[Publication]: Role of endoplasmic reticulum stress in impaired neonatal lung growth and bronchopulmonary dysplasia August 23, 2022
In this work, rngen, together with researchers from the Medical College of Wisconsin, demonstrated that oxygen treatment in rat pups causes stress to the endoplasmic reticulum of the neonatal lungs. This elicits a feedback loop to aggravate inflammation and impairs neonatal lung development, resulting in bronchopulmonary dysplasia. KYC effectively mitigates oxygen-induced ER stress and attenuates the severity of bronchopulmonary dysplasia.
[View publication: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269564]
[News]: ReNeuroGen: Innovators in Action March 2022
Drs. Pritchard and Naylor interviewed about their ideas of using KYC to treat the NFL associated injury Chronic Traumatic Encephalopathy (CTE).
[Read More: https://mkestartup.news/reneurogen-innovators-in-action]